Research ExplorerPublicationsAssociations of the vasoactive peptides CT-proET-1 and MR-pr...

Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium

Standard

Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium. / Sujana, Chaterina; Salomaa, Veikko; Kee, Frank; Seissler, Jochen; Jousilahti, Pekka; Neville, Charlotte; Then, Cornelia; Koenig, Wolfgang; Kuulasmaa, Kari; Reinikainen, Jaakko; Blankenberg, Stefan; Herder, Christian; Mansmann, Ulrich; Peters, Annette; Thorand, Barbara; BiomarCaRE Consortium.

In: CARDIOVASC DIABETOL, Vol. 21, No. 1, 99, 09.06.2022.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Sujana, C, Salomaa, V, Kee, F, Seissler, J, Jousilahti, P, Neville, C, Then, C, Koenig, W, Kuulasmaa, K, Reinikainen, J, Blankenberg, S, Herder, C, Mansmann, U, Peters, A, Thorand, B & BiomarCaRE Consortium 2022, 'Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium', CARDIOVASC DIABETOL, vol. 21, no. 1, 99. https://doi.org/10.1186/s12933-022-01513-9

APA

Sujana, C., Salomaa, V., Kee, F., Seissler, J., Jousilahti, P., Neville, C., Then, C., Koenig, W., Kuulasmaa, K., Reinikainen, J., Blankenberg, S., Herder, C., Mansmann, U., Peters, A., Thorand, B., & BiomarCaRE Consortium (2022). Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium. CARDIOVASC DIABETOL, 21(1), [99]. https://doi.org/10.1186/s12933-022-01513-9

Vancouver

Sujana C, Salomaa V, Kee F, Seissler J, Jousilahti P, Neville C et al. Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium. CARDIOVASC DIABETOL. 2022 Jun 9;21(1). 99. https://doi.org/10.1186/s12933-022-01513-9

Bibtex

@article{1a00e7cb48794a5d8b9ec23e61eeb2ac,
title = "Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium",
abstract = "BACKGROUND: Endothelin-1 (ET-1) and adrenomedullin (ADM) are commonly known as vasoactive peptides that regulate vascular homeostasis. Less recognised is the fact that both peptides could affect glucose metabolism. Here, we investigated whether ET-1 and ADM, measured as C-terminal-proET-1 (CT-proET-1) and mid-regional-proADM (MR-proADM), respectively, were associated with incident type 2 diabetes.METHODS: Based on the population-based Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) Consortium data, we performed a prospective cohort study to examine associations of CT-proET-1 and MR-proADM with incident type 2 diabetes in 12,006 participants. During a median follow-up time of 13.8 years, 862 participants developed type 2 diabetes. The associations were examined in Cox proportional hazard models. Additionally, we performed two-sample Mendelian randomisation analyses using published data.RESULTS: CT-proET-1 and MR-proADM were positively associated with incident type 2 diabetes. The multivariable hazard ratios (HRs) [95% confidence intervals (CI)] were 1.10 [1.03; 1.18], P = 0.008 per 1-SD increase of CT-proET-1 and 1.11 [1.02; 1.21], P = 0.016 per 1-SD increase of log MR-proADM, respectively. We observed a stronger association of MR-proADM with incident type 2 diabetes in obese than in non-obese individuals (P-interaction with BMI < 0.001). The HRs [95%CIs] were 1.19 [1.05; 1.34], P = 0.005 and 1.02 [0.90; 1.15], P = 0.741 in obese and non-obese individuals, respectively. Our Mendelian randomisation analyses yielded a significant association of CT-proET-1, but not of MR-proADM with type 2 diabetes risk.CONCLUSIONS: Higher concentrations of CT-proET-1 and MR-proADM are associated with incident type 2 diabetes, but our Mendelian randomisation analysis suggests a probable causal link for CT-proET-1 only. The association of MR-proADM seems to be modified by body composition.",
keywords = "Adrenomedullin, Biomarkers, Diabetes Mellitus, Type 2/diagnosis, Endothelin-1, Heart Disease Risk Factors, Humans, Obesity, Peptide Fragments, Prospective Studies, Protein Precursors",
author = "Chaterina Sujana and Veikko Salomaa and Frank Kee and Jochen Seissler and Pekka Jousilahti and Charlotte Neville and Cornelia Then and Wolfgang Koenig and Kari Kuulasmaa and Jaakko Reinikainen and Stefan Blankenberg and Tanja Zeller and Christian Herder and Ulrich Mansmann and Annette Peters and Barbara Thorand and {BiomarCaRE Consortium}",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = jun,
day = "9",
doi = "10.1186/s12933-022-01513-9",
language = "English",
volume = "21",
journal = "CARDIOVASC DIABETOL",
issn = "1475-2840",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium

AU - Sujana, Chaterina

AU - Salomaa, Veikko

AU - Kee, Frank

AU - Seissler, Jochen

AU - Jousilahti, Pekka

AU - Neville, Charlotte

AU - Then, Cornelia

AU - Koenig, Wolfgang

AU - Kuulasmaa, Kari

AU - Reinikainen, Jaakko

AU - Blankenberg, Stefan

AU - Zeller, Tanja

AU - Herder, Christian

AU - Mansmann, Ulrich

AU - Peters, Annette

AU - Thorand, Barbara

AU - BiomarCaRE Consortium

N1 - © 2022. The Author(s).

PY - 2022/6/9

Y1 - 2022/6/9

N2 - BACKGROUND: Endothelin-1 (ET-1) and adrenomedullin (ADM) are commonly known as vasoactive peptides that regulate vascular homeostasis. Less recognised is the fact that both peptides could affect glucose metabolism. Here, we investigated whether ET-1 and ADM, measured as C-terminal-proET-1 (CT-proET-1) and mid-regional-proADM (MR-proADM), respectively, were associated with incident type 2 diabetes.METHODS: Based on the population-based Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) Consortium data, we performed a prospective cohort study to examine associations of CT-proET-1 and MR-proADM with incident type 2 diabetes in 12,006 participants. During a median follow-up time of 13.8 years, 862 participants developed type 2 diabetes. The associations were examined in Cox proportional hazard models. Additionally, we performed two-sample Mendelian randomisation analyses using published data.RESULTS: CT-proET-1 and MR-proADM were positively associated with incident type 2 diabetes. The multivariable hazard ratios (HRs) [95% confidence intervals (CI)] were 1.10 [1.03; 1.18], P = 0.008 per 1-SD increase of CT-proET-1 and 1.11 [1.02; 1.21], P = 0.016 per 1-SD increase of log MR-proADM, respectively. We observed a stronger association of MR-proADM with incident type 2 diabetes in obese than in non-obese individuals (P-interaction with BMI < 0.001). The HRs [95%CIs] were 1.19 [1.05; 1.34], P = 0.005 and 1.02 [0.90; 1.15], P = 0.741 in obese and non-obese individuals, respectively. Our Mendelian randomisation analyses yielded a significant association of CT-proET-1, but not of MR-proADM with type 2 diabetes risk.CONCLUSIONS: Higher concentrations of CT-proET-1 and MR-proADM are associated with incident type 2 diabetes, but our Mendelian randomisation analysis suggests a probable causal link for CT-proET-1 only. The association of MR-proADM seems to be modified by body composition.

AB - BACKGROUND: Endothelin-1 (ET-1) and adrenomedullin (ADM) are commonly known as vasoactive peptides that regulate vascular homeostasis. Less recognised is the fact that both peptides could affect glucose metabolism. Here, we investigated whether ET-1 and ADM, measured as C-terminal-proET-1 (CT-proET-1) and mid-regional-proADM (MR-proADM), respectively, were associated with incident type 2 diabetes.METHODS: Based on the population-based Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) Consortium data, we performed a prospective cohort study to examine associations of CT-proET-1 and MR-proADM with incident type 2 diabetes in 12,006 participants. During a median follow-up time of 13.8 years, 862 participants developed type 2 diabetes. The associations were examined in Cox proportional hazard models. Additionally, we performed two-sample Mendelian randomisation analyses using published data.RESULTS: CT-proET-1 and MR-proADM were positively associated with incident type 2 diabetes. The multivariable hazard ratios (HRs) [95% confidence intervals (CI)] were 1.10 [1.03; 1.18], P = 0.008 per 1-SD increase of CT-proET-1 and 1.11 [1.02; 1.21], P = 0.016 per 1-SD increase of log MR-proADM, respectively. We observed a stronger association of MR-proADM with incident type 2 diabetes in obese than in non-obese individuals (P-interaction with BMI < 0.001). The HRs [95%CIs] were 1.19 [1.05; 1.34], P = 0.005 and 1.02 [0.90; 1.15], P = 0.741 in obese and non-obese individuals, respectively. Our Mendelian randomisation analyses yielded a significant association of CT-proET-1, but not of MR-proADM with type 2 diabetes risk.CONCLUSIONS: Higher concentrations of CT-proET-1 and MR-proADM are associated with incident type 2 diabetes, but our Mendelian randomisation analysis suggests a probable causal link for CT-proET-1 only. The association of MR-proADM seems to be modified by body composition.

KW - Adrenomedullin

KW - Biomarkers

KW - Diabetes Mellitus, Type 2/diagnosis

KW - Endothelin-1

KW - Heart Disease Risk Factors

KW - Humans

KW - Obesity

KW - Peptide Fragments

KW - Prospective Studies

KW - Protein Precursors

U2 - 10.1186/s12933-022-01513-9

DO - 10.1186/s12933-022-01513-9

M3 - SCORING: Journal article

C2 - 35681200

VL - 21

JO - CARDIOVASC DIABETOL

JF - CARDIOVASC DIABETOL

SN - 1475-2840

IS - 1

M1 - 99

ER -